Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer
- More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation
- Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing
- Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, transitions to Chief Development Officer
Barcelona, Spain, 24 September 2026: Ona Therapeutics (“Ona”), a clinical-stage biotech developing a novel, patient-derived, target-focused portfolio of next-generation ADCs to overcome growing treatment resistance across major cancer indications, today announced continued progress in the Phase 1a clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers. More than half of the patients planned for the study have already been enrolled, with the trial continuing to progress through dose escalation.
